Indication
x POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

Mechanism of action (MOA).

In vitro, POMALYST has been demonstrated to1:

  • Inhibit the proliferation and induce apoptosis of hematopoietic tumor cells
  • Inhibit the proliferation of lenalidomide-resistant multiple myeloma cell lines
  • Have immunomodulatory activity. Pomalidomide enhanced T cell– and natural killer cell–mediated immunity

Based on preclinical studies:

POMALYST + dex (Pd) induces cytotoxicity in REVLIMID® (lenalidomide)*-sensitive
and -resistant cells1†

POMALYST® (pomalidomide ) Mechanism of Action

*Please see full Prescribing Information, including Boxed WARNINGS, for REVLIMID.

Based on preclinical in vivo and in vitro studies, the mechanism of action statements are not meant to imply clinical outcomes.

In combination with dex.

§In in vitro models.

See how POMALYST + dex (Pd) stimulates immune function and kills multiple myeloma cells.1

Mechanism of Action

Explore the mechanism of action of POMALYST.

Based on preclinical in vivo and in vitro studies, the mechanism of action statements are not meant to imply clinical outcomes.

View Video Transcript

Hide Video Transcript

Pomalidomide is an immunomodulatory agent with antineoplastic activity [1].

Pomalidomide has been shown to have in vitro activity that overcomes lenalidomide resistance [1]. In addition to the immunomodulatory and antineoplastic activity, pomalidomide demonstrated antiangiogenic activity in an in vitro umbilical cord model and in vivo [1,2].

The antineoplastic activity of pomalidomide has been established in in vitro cellular assays. Pomalidomide has been shown to inhibit proliferation and induce apoptosis of hematopoietic tumor cells [1].

Pomalidomide also inhibited the proliferation of lenalidomide-resistant multiple myeloma cell lines [1].

Pomalidomide synergized with dexamethasone and induced tumor cell apoptosis in both lenalidomide-resistant and lenalidomide-sensitive cell lines [1].

Pomalidomide has been shown to have immunomodulatory activity [1]. Pomalidomide enhanced T cell- and natural killer cell-mediated immunity [1].

It also inhibited production of proinflammatory cytokines, such as TNF-α and IL-6, by monocytes [1,2].

Pomalidomide also demonstrated antiangiogenic properties [1,2]. This activity is supported by an in vivo mouse tumor model and an in vitro umbilical cord model [1].

Pomalidomide is an immunomodulatory and antineoplastic agent with in vitro activity that overcomes lenalidomide resistance [1]. Based on pre-clinical findings, pomalidomide, in combination with low-dose dexamethasone, was evaluated in a Phase 3 multi-center, randomized, open-label study [1].

[Voiceover does not read the disclaimer]

[copy]

Please see accompanying full Prescribing Information, including Boxed WARNINGS.

[Voiceover does not read the references]

References:

  1. POMALYST (pomalidomide) Capsules PI.
  2. Terpos E, Kanellias N, Christoulas D, et al. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther. 2013;6:531-538.

[Voiceover does not read end matter]

© 2015 Celgene Corporation 12/15 US-POM150057

dex, dexamethasone; IL, interleukin; IMiD, immunomodulatory; NK, natural killer; NKT, natural killer T; Pd, POMALYST + dexamethasone; PI, proteasome inhibitor; TNF, tumor necrosis factor.

References: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp. 2. REVLIMID [package insert]. Summit, NJ: Celgene Corp. 3. Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res. 2012;36(01):S3-S12. 4. Görgün G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010;116(17):3227-3237. 5. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128(2):192-203. 6. Sehgal K, Das R, Zhang L, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015;125(26):4042-4051. 7. Rychak E, Mendy D, Shi T, et al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol. 2016;172(6):889-901.

Patient Access, Reimbursement, and Co-Pay Support.

Access and Financial Resources